tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Cosmo Pharmaceuticals Unaffected by US Tariffs, Maintains Growth Momentum

Story Highlights
Cosmo Pharmaceuticals Unaffected by US Tariffs, Maintains Growth Momentum

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

COSMO Pharmaceuticals N.V. ( (CH:COPN) ) just unveiled an announcement.

Cosmo Pharmaceuticals announced that potential US tariffs on Swiss pharmaceutical companies will not impact its operations, as it does not export from Switzerland to the US and has long-term global contracts. The company remains optimistic about its growth trajectory, bolstered by strong fundamentals and increased EBITDA, and continues to deliver stable results to shareholders.

The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF133.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.

More about COSMO Pharmaceuticals N.V.

Cosmo Pharmaceuticals is a life-science company specializing in MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs and manufactures advanced medical solutions, aiming to improve healthcare standards globally. Founded in 1997, Cosmo is headquartered in Dublin, Ireland, with additional offices in the USA and Italy.

Average Trading Volume: 25,014

Technical Sentiment Signal: Sell

Current Market Cap: CHF936.2M

Learn more about COPN stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1